Stocks · News reference

8-K filing — Keros Therapeutics, Inc. (KROS)

Sep 29, 2026, 12:01 PMSEC EDGAR

Filed: 2026-09-29 AccNo: 0001664710-26-000059 Size: 167 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 29, 2026, 12:04 PMBenzinga Newsdesk
Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial
ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis ("MF") and anemia on concurrent ruxolitinib
KROS TAK
BenzingaSep 28, 2026, 12:03 PMBenzinga Newsdesk
Keros Therapeutics Doses First Patient In Phase 2 Clinical Study Of Rinvatercept In Patients With Duchenne Muscular Dystrophy
Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that
KROS
BenzingaSep 10, 2026, 8:06 PMBenzinga Newsdesk
Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners
SEC.
KROS